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Introduction 
The outlook for Cystic Fibrosis (CF) patients has dramatically 
improved over the last 10–20 years, mostly due to rigorous antibiotic 
treatment. The average life expectancy is now 40 years [1] and a child born 
with CF in 2016 is predicted to well live beyond 50 [2]. However, airways 
infection and the subsequent inflammation are deleterious for CF patients. 
Infection with Pseudomonas aeruginosa (P. aeruginosa) still represents 
the leading cause of chronic inflammation, lung function decline and 
ultimately death in CF patients [3]. Recently drugs have been approved 
that target the modified protein CFTR (cystic fibrosis transmembrane 
conductance regulator) improving expression and function of CFTR.
The small molecule CFTR potentiator Ivacaftor enhances the 
function of CFTR which reaches the cell membrane (class III mutation, 
e.g. Gly551Asp-CFTR) [4] and its use in CF patients with the Gly551Asp 
mutation has improved lung function and quality of life [5]. Whilst 
the development of Ivacaftor (Kalydeco) is promising, this mutation 
accounts for only 5% of CF cases. A greater clinical benefit may be seen 
through the development of CFTR correctors that particularly target 
the most common class II mutation, Phe508del. The CFTR corrector, 
Lumacaftor, helps to bypass the degradation of Phe508del-CFTR. 
Once at the cell membrane, potentiator treatment can enhance the 
function of this CFTR. Randomised clinical trials using dual therapy 
(corrector/potentiator, Orkambi) reported an improvement in FEV1 
(forced expiratory volume in one second) and reduced frequency 
of pulmonary exacerbations, hospitalization and use of intravenous 
antibiotics in patients homozygous for Phe508del [6]. However, 
although successfully improving expression and function of CFTR, 
airway inflammation was not reduced. In CF patients aged 6 years and 
above with Gly551Asp-CFTR, 6 months of treatment with Ivacaftor 
did not reduce inflammatory markers in sputum such as IL-1, IL-6 
and IL-8 [7] and heterogeneous responses to the corrector/potentiator 
treatment have been reported in patients homozygous for Phe508del-
CFTR [8]. This suggests that CFTR correction/potentiation may not 
directly improve the underlying compromised immune response, thus 
there is still an unmet need to normalise the inflammatory response 
in CF airways. Here we focus on the regulation of NF-κB-driven lung 
inflammation in CF by the negative regulator A20.
The ability to respond to pathogens is critical for health and survival 
and pathogens are identified by epithelial and immune cells through 
pattern recognition molecules, namely the toll-like receptors (TLRs). 
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Abstract
Cystic Fibrosis (CF) is characterised by prolonged and exaggerated airways inflammation. Despite recent 
developments to overcome the underlying functional defect in CFTR (cystic fibrosis transmembrane conductance 
regulator); there is still an unmet need to reduce the inflammatory response. The NF-κB regulator A20 is a key target to 
normalise the inflammatory response and is reduced in CF. Here, we describe the plethora of functions of A20 as they 
apply to innate immune function within the airways. Pharmacological compounds can enhance A20 mRNA and protein 
expression, but we observed a blunted effect in CF primary epithelial cells. In CF cells pre-treatment with gibberellic 
acid (GA3) shows anti-inflammatory effects only in some patients. We show that cells with higher basal p38 expression 
respond with an increase in pro-inflammatory cytokines. Furthermore, all CF PNECs show increased p38 mRNA when 
stimulated in the presence of GA3. Our results suggest that those patients may benefit from therapeutics targeting p38. 
Several studies [9-11] have shown altered TLR-4 expression in CF 
airway epithelial cells, leading to increased expression of inflammatory 
cytokines [12]. Such overall deranged immune response in CF is 
largely driven by the transcription factor NF-κB and a lack of intrinsic 
downregulation of NF-κB [13,14].
The ubiquitinating/deubiquitinating enzyme A20 has recently 
become a subject of great interest due to its identification as a 
multifaceted modulator of immunity and disease and its function as 
one of the key regulators of NF-κB activation [15]. A20 was initially 
identified as a tumour suppressor gene [16], but polymorphisms 
and reduced expressions have since been implicated in chronic 
inflammatory conditions such as inflammatory bowel disease, systemic 
lupus erythematosus, type 1 diabetes, psoriasis, rheumatoid arthritis 
and multiple sclerosis, where A20 could serve as a susceptibility gene/
biomarker of disease development [17,18].
Basal expression of A20 is low in most cell types; however, A20 is 
rapidly induced upon stimulation of NF-κB [18]. Increased expression 
of A20 is associated with an inhibition of NF-κB as shown in mouse 
embryonic fibroblasts [19]. A20 deficient mice develop severe, systemic 
inflammation without stimulation as they are not able to terminate NF-
κB signalling resulting in premature death [20]. 
A20 in the airways
In the airways, stimulation with bacterial lipopolysaccharide (LPS) 
and peptidoglycan PGN upregulates A20 mRNA in primary cultured 
airway epithelial cells and H292 cells and inhibits TLR2 and TLR4 
mediated IL-8 synthesis [21]. Enhanced A20 mRNA expression occurs 
following infection of mice with P. aeruginosa [22] We have previously 
shown that the prolonged NF-κB driven inflammatory response in CF 
airway epithelial cells is associated with reduced expression of A20 [23] 
Citation: McCallum K, El Banna A, Ennis M, Schock BC (2016) Chronic Inflammation in CF Airways - A Persistent Issue for A20. J Genet Syndr Gene 
Ther 7: 313. doi: 10.4172/2157-7412.1000313
Page 2 of 7
Volume 7 • Issue 5 • 1000313J Genet Syndr Gene Ther, an open access journalISSN: 2157-7412 
and most importantly this lack of A20 correlates with reduced lung 
function in patients with CF [24]. Onose et al. described virus induced 
induction of A20 in human bronchial epithelial cell lines and mouse 
lung homogenates. Furthermore, transient overexpression of A20 
in epithelial cell lines inhibited NF-κB activation and inflammation 
following influenza infection [25]. However, in in vivo experiments in 
mice selective A20 deficiency in Clara cells appears to protect against 
influenza A virus infection with reduced host innate and adaptive 
immune responses and lung damage, which was not due to decreased 
viral replication in these cells. In contrast, mice in which A20 was 
selectively knocked down in myeloid cells/macrophages show increased 
NF-κB and IRF3 driven inflammation in response to influenza 
infection, suggesting a cell type specific effect of A20 or an additional 
late response effect (adaptive immunity) [26]. However, in response to 
lethal doses of influenza A20 knockout mice appeared protected [27]. 
The diverse functions of A20
The action of A20 within inflammatory NF-κB activation pathways 
has been extensively investigated. Upon activation of the canonical NF-
κB pathway through LPS binding to TLR4, A20 acts as an endogenous 
regulator on the E3 ligase TRAF6 to reduce NF-κB activation and 
subsequent translocation [18]. Signalling pathways initiated by TNFα 
and IL-1β leading to NF-κB activation are also regulated by A20 [15]. 
Furthermore, A20 negatively regulates the TLR induced inflammasome 
and thereby the release of IL-1 (and other members of the IL-1family) 
[28] and activation pathways of IL-17R, NOD receptors, RIG-I 
receptor and T-cell receptor [29], emphasising its key role in regulating 
inflammation (Figure 1).
Figure 1: Summarises the main functions of A20 in the airways within the inflammatory context.
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A20 is also involved in the promotion of tolerance to (commensal) 
bacteria. In the rat intestine A20 prominently localizes to the luminal 
side of the villus enterocytes, while lower (more protected) parts of 
the crypts display relatively low levels of A20 [30]. In culture, repeated 
stimulation of rat enterocytes (e.g. IEC6/18 cells) with LPS or of human 
monocytic THP-1 cells with Pam3CSK4, TNF-α or IL-1β results in 
an inhibition of subsequent LPS-induced activation of p38, c-Jun and 
NF-κB lasting up to 28 h in proliferating and over 72 h in stationary 
cultures [30] (Figure 1). Moreover, antibiotic treatment of rats led to‘gut 
decontamination’ and reduced A20 levels in the epithelium [30].
Furthermore, A20 appears to be important in endo-lysosome 
formation and therefore may play an important role in antigen 
processing. In cultured human intestinal epithelial cells (Caco-2 
and HT-29), A20 is needed for fusion of endosomes and lysosomes 
and therefore the degradation of microbial products such as SEB 
and exogenous allergens such as ovalbumin [31,32]. A20-deficient 
Caco-2 cells show significantly lower endo-lysosome formation 
and subsequent transport of OVA to the basolateral side ultimately 
conserving antigenicity [32]. Therefore, during inflammation, A20 
may contribute to the tethering of the endosome to lysosome itself, 
but the mechanism by which A20 contributes to membrane fusion 
needs further investigation. Moreover, mice lacking A20 specifically 
in their intestinal epithelial cells do not show spontaneous intestinal 
inflammation but exhibited hyper-responsiveness to TNF-induced 
apoptosis, resulting in a breakdown of the intestinal barrier permitting 
commensal bacterial to infiltrate and cause systemic inflammation [33] 
(Figure 1). Commensal bacteria in the lung may also promote tolerance 
in airway epithelial (and immune cells) but lack of A20 in CF airway 
epithelial cells, accelerated by frequent antibiotic therapy may prohibit 
appropriate development of tolerance. Furthermore, stimulation of CF 
airway epithelial cells with LPS results in TLR4 being preferentially 
recycled and not targeted to endo-lysosomal degradation [12], which 
may contribute to the repeated stimulation of the epithelium. Equally, 
processing of inhaled antigens together with a reduced barrier function 
of the airway epithelium would significantly impact the inflammatory 
responses in atopic asthma. Similarly, A20 is important in controlling 
TLR4 induced autophagy. For instance, ubiquitination of Beclin1 and 
subsequent oligomerization activates of PI 3KC3 and promotes the 
formation of autophagosomes. In murine macrophages (RAW 264.7) 
and human embryonic kidney cells (HEK 293T), A20 limits TLR4 
induced autophagy by deubiquitinating TRAF6 and Beclin1 [34] 
(Figure 1).
However, in high A20 mRNA expressing murine F4/80hi 
macrophages (spleen, peritoneum and kidney) NF-κB activation 
is enhanced by autophagic depletion of A20. This allows these 
macrophages to release chemokines for the recruitment of neutrophils.
Finally, A20 plays an important role in apoptosis, a process of 
cell suicide in response to a variety of stimuli including infections, 
necessary to maintain immune and tissue homeostasis. Apoptosis is 
initiated through one of two pathways: Intrinsic (intracellular signals) 
or extrinsic (receptor ligand binding) with both pathways converging 
on the same set of executioner caspases. During intrinsically induced 
apoptosis, A20 can inhibit apoptosis and promote cell survival through 
its modulation of TNFα induced apoptosis independent of NF-κB 
termination [15], which in part may be mediated by direct binding 
to cIAP1/2 and preventing the association between TRAF2 and RIP1 
[35]. Furthermore, in cell lines (e.g. HeLa, HEK293 and MEFs) and 
β-cells in type 1 diabetes A20 can suppress c-jun N-terminal kinase 
(JNK) through ubiquitination/degradation of the apoptosis signal 
regulating kinase 1 (ASK1), while TNFα stimulation in the absence of 
A20 results in persistently active JNK [36,37]. However, pro-apoptotic 
functions of A20 have also been identified, mostly likely due to the 
termination of NF-κB and subsequent loss of anti-apoptotic proteins, 
BCL-2 and BCL-X [29]. This suggests that the effect of A20 is a balance 
between its own innate anti-apoptotic functions and the expression 
of NF-κB mediated anti-apoptotic proteins which may be hindered 
through repression by A20. Extrinsically induced apoptosis may also 
be regulated through A20. TRAIL (TNF related apoptosis inducing 
ligand) bound to death receptors DR4/5 or FasL bound to Fas induce 
pro-apoptotic signalling and recruitment of FADD (Fas associated 
protein with death domain) and caspase-8. This leads to the formation 
of the death inducing signalling complex (DISC). A20 is recruited to 
the DISC, overall inhibiting the downstream activation of caspase-8 
[38,39]. 
Taken together the critical contribution of A20 in immune 
tolerance (intestinal and pulmonary), antigen processing, epithelial 
barrier function and the well-established role in inflammation 
and apoptosis, A20 has an essential role in maintaining immune 
homeostasis. Therefore, the apparent lack of A20 described in epithelial 
cells of patients with CF and asthma [23,40] has important implications 
for the overall immune responses in these chronic airway diseases. Not 
surprisingly, A20 has recently been identified as a target enzyme for 
new anti-inflammatory drugs [41,42].
A20 as a target for anti-inflammatory drug development in 
CF
In line with the bacterial induction of immune-regulatory A20, 
earlier work suggested the benefit of A20 induction by inactivated 
bacteria (P. aeruginosa) in allergic airway inflammation [43]. Using 
airway epithelial cells (cell lines and primary cells from control 
subjects), we have previously shown that pharmacological induction 
of A20 through the plant diterpenoid gibberellin (GA3) is anti-
inflammatory [42]. Furthermore, using an advanced bioinformatics 
approach that established the link between disease-specific gene 
expression and the gene modification through already licensed drugs, 
statistically significant connections Map (sscMap) [44] we were able to 
predict drugs already licenced for the use in humans, which through the 
process of drug repositioning could be made available to CF patients. 
Our candidate drugs predicted to increase A20 gene expression 
were quercetin and the macrolide ikarugamycin. However, although 
successful in non-CF airway cells, CF epithelial cells showed an overall 
blunted (delayed and reduced) response with respect to A20 induction 
and the subsequent reduction in inflammation [41].
Using cell lines (16HBE14o- and CFBE41o-), gibberellin (GA3) 
pre-treatment showed a similar reduction in IL-8 release in non-CF 
and CF epithelial cells. However, CF primary nasal epithelial cells 
(PNECs) compared to non-CF PNECs showed an individually diverse 
response, with some patients’ cells showing a reduction in LPS induced 
IL-8 release in response to GA3 treatment, while others showed no 
response or a higher release of IL-8 (Figure 2). CF PNECs also showed a 
blunted response with respect to A20 mRNA induction and p65 mRNA 
reduction in response to GA3 treatment compared to non-CF PNECs ().
To further examine the observed pro-inflammatory effect of GA3 
in CF PNECs, we determined p38 mRNA in CF and non-CF PNECs. 
Figure 3 shows p38 mRNA expression in GA3 pre-treated CF PNECs 
and Table 1 shows selected individual data form the same CF epithelial 
cultures. Compared to non-CF PNECs, CF PNECs show increased 
basal and stimulated p38 mRNA expression (4 h LPS). Pre-incubation 
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of cells with gibberellin alone did not change p38 mRNA expression. 
When investigating the response of selected PNECs individually, we 
observed two different response types of CF PNECs, those in which 
the pre-treatment with gibberellin lead to an increase of IL-8 release 
(CF#7,8, 157) and those which showed a decrease in IL-8 release similar 
to non-CF cells (CF#12,14, 34). Analyses of p38 mRNA in these cells 
revealed that those in which gibberellin had a pro-inflammatory effect 
were PNECs with the higher basal p38 expression, while those which 
responded to gibberellin with a reduction in IL-8 had lower basal p38 
mRNA expression. Table 1 shows IL-8 (pg/ml, stimulated with LPS in 
the presence and absence of GA3), p38 mRNA expression (basally and 
4 h after LPS, when expression peaks, in the presence and absence of 
GA3) as well as A20 mRNA expression (basally and 1h after LPS, in the 
presence and absence of GA3) of selected CF and non-CF PNECs. CF 
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Figure 2: Il-8 release from non-CF (purple) and CF (green) primary nasal epithelial cells stimulated with LPS (10 µg/ml) in the presence or absence of gibberellin 
GA3 (30 µm).
Figure 3: A20, p65 and p38 mRNA expression in non-CF (grey) and CF (green) primary nasal epithelial cells stimulated with LPS (10 µg/ml) in the presence or 
absence of gibberellin GA3 (30 µm, 1 h).
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PNECs show a high variation in basal p38 mRNA expression (high: CF 
#7, #8, #157; low: CF #12, #14, #34), but they all are able to induce p38 in 
response to GA3, an induction that non-CF PNECs do not show (Table 
1). Interestingly, when expressing the mRNA data as change from basal 
expression, CF cells with higher basal p38 mRNA levels (CF #7, #8, 
#157) show the ability to increase A20 mRNA (%) similarly to non-CF 
cells (Table 1). However, the data confirm reduced A20 induction in 
these CF PNECs and may suggest that other inflammatory pathways 
such as MAPK-p38 may play a role in the increased IL-8 response to 
GA3.
Materials and Methods
Cell culture and stimulations
The bronchial epithelial cell lines 16HBE14o- (control) and 
CFBE41o-(CF, F508del/F508del) were obtained from Gruenert, UCSF, 
USA and cultured as described [23]. Primary nasal epithelial cells 
(PNECs) from healthy volunteers and CF patients (all F508del/F508del) 
were cultured as described [42]. Control participants did not have any 
acute airways disease at the time of sampling, or a history of any chronic 
airways inflammation. The Research Ethics Committee of Northern 
Ireland (07/NIR02/23) approved the study and all participants provided 
informed consent. Cells were exposed to gibberellic acid (GA3, Sigma 
63492, 30 µM) for 1 h prior to LPS stimulation (P. aeruginosa LPS, 
serotype 10, Sigma-Aldrich, L9143, 10 µg/ml, upto 24 h). 
Determination of LPS induced interleukin-8 release
The concentrations of IL-8 in cell-free culture supernatants were 
measured by a commercially available ELISA (PeproTech EC Ltd.) 
according to the manufacturer’s instructions. 
Real time qPCR
Total RNA was extracted using the GenElute™ Mammalian Total RNA 
Miniprep Kit (RTN350, Sigma-Aldrich) and quantified on a Nanodrop 
(Thermo Scientific). Equal amounts of RNA (250 ng) were reverse 
transcribed into cDNA (High-Capacity cDNA Reverse Transcription Kit, 
Applied Biosystems™). Primers were designed using gene accession numbers 
and Primer3 open-source PCR primer design software and obtained from 
Invitrogen Ltd. (Paisley, UK) (p38 fwd: gcc aga aac tcc ttt tgc tg; p38 reverse: 
ctc ccc aaa cca aga agt ca). A20 and β-actin primer sequences previously 
described [42]. Relative expression to β-actin was calculated as 2-ΔΔCt. Jurkat 
cell cDNA acted as an internal calibrator for all experiments and was used 
to determine differences in basal gene expression.
Statistical analysis 
All data are presented as the means ± SEM. Differences between 
groups were analysed using the Kruskal-Wallis non-parametric 
ANOVA with Dunn’s post-test if the Kruskal Wallis test was significant 
(*p<0.05, **p<0.01, ***p<0.001). GraphPad Prism (La Jolla, California) 
was used to plot graphs and to analyse the data.
Discussion
The effect of p38 in LPS induced inflammation in CF
CF lung disease is characterised by increased responses to bacterial 
infections, mainly driven by TLRs and NF-κB signalling. A key feature 
of CF inflammation is the neutrophil-dominated response, mediated 
by higher than normal levels of the chemoattractant IL-8. In non-CF 
airways, TLR activation leads to transcription factor NF-κB induced 
translation of IL-8. Within the TLR-NF-κB activation pathway, A20 is 
one of the key negative regulators of this response, ultimately leading 
to a timely termination of the inflammation. Induction of A20 by the 
plant derived diterpenoid gibberellin (GA3) decreases NF-κB activation 
and subsequent IL-8 release in airway epithelial cells [42]. However, CF 
airways cells not only have lower basal and stimulated levels of A20 
than non-CF cells, their response to gibberellin and other A20 inducing 
drugs [41] is blunted, especially in primary airway epithelial cells. 
Subsequently, CF cells show no significant reduction in IL-8 release in 
response to LPS when pre-treated with these A20 inducing drugs. More 
so, we found that when cells are pre-treated with GA3, cells from some 
patients show an increase in IL-8 secretion. Additionally, our recent 
data demonstrated that CF airway epithelial cells are able to induce 
and maintain A20 mRNA [41] when stimulated with higher doses of 
ikarugamycin (1 µm), suggesting that A20 can be upregulated to oppose 
drug induced apoptosis, but further work is needed to investigate the 
apoptotic pathways involved.
In inflammation, IL-8 translation can be maintained at higher levels 
by mRNA stabilisation through the activity of MAPK p38 [45]. Global 
gene expression in immortalized human CF and non-CF airway cells 
showed an inflammatory gene signature involving MAPK signalling 
and the hyper-inflammatory phenotype in response to microbial 
stimulation was found to be dependent on p38 activity [46]. CF lung 
biopsies showed increased immunoreactivity for p38 MAPK activity 
markers and CFTR Phe508del/Phe508del airway epithelial cells lines 
(NuLi) confirmed a further increase in p38 activity when stimulated 
with P. aeruginosa [47]. Furthermore, the p38-MAPK inhibitor 
SB203580 significantly controlled LPS induced inflammation in CF 
nasal biopsies tissues [48] rendering the p38 signalling pathway as a 
possible therapeutic target [49].
Our study investigating the induction of the NF-κB regulator 
A20 in PNECs indicated individual differences with respect to basal 
IL-8 [pg/ml] Relative p38 mRNA (2-∆∆ct) Relative A20 mRNA (2-∆∆ct)
LPS 24 h GA3+LPS 24 h Change [%] Basal LPS 4 h GA3+LPS 4 h Basal GA3+LPS 1h Increase [%]
Non-CF#5 269.65 195.21 72.389 0.44 0.39 0.35 1.66 3.21 193.3
Non-CF#6 184.99 71.19 38.48 0.30 0.32 0.1 1.29 2.45 189.9
Non-CF#24 401.85 257.69 64.13 0.21 0.29 0.52 1.49 3.54 209.4
CF#7 637.81 1408.18 220.78 1.94 1.36 2.42 0.61 2.22 363.9
CF#8 795.54 1656.92 208.28 1.02 2.53 3.26 0.38 1.09 286.8
CF#157 356.30 1008.41 283.02 1.67 1.28 1.13 0.70 1.47 210.0
CF#12 367.64 251.22 68.33 0.63 3.78 5.63 0.99 0.62 63.0
CF#14 612.52 489.64 79.94 0.58 2.84 4.12 1.35 1.03 75.6
CF#34 261.24 169.12 64.74 0.81 3.31 3.87 1.14 1.93 136.8
Table 1: LPS induced IL-8 release (24 h) and p38 mRNA expression [basally and 4 h after stimulation from non-CF and CF primary epithelial cells. Cells were stimulated 
with LPS (10 µg/ml) in the presence or absence of gibberellin (GA3, 30 µm) and mRNA for p38 and A20 determined.
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and LPS stimulated p38 mRNA expression. The effect of the A20 
inducer gibberellic acid on p38 MAPK signalling is not known, but our 
observational data suggest that in those patients with higher basal p38 
expression treatment with GA3 has a pro-inflammatory effect (increase 
IL-8 release). The inhibition of NF-κB signalling via A20 at the levels of 
TRAF6 may also affect p38 MAPK (Figure 1).
Moreover, in activated macrophages (RAW cells) p38 has been 
described as a transcriptional regulator of A20 via the transcription 
factor C/EBPbeta [50]. Our observation that increased basal p38 
expression is associated with lower A20 induction cannot be explained 
by p38 increasing the transcription factor binding to the A20 promoter. 
Furthermore, although CF PNECs responding to GA3+LPS with a 
reduction of IL-8 (24 h) also show the highest levels of GA3+LPS 
induced p38 expression (peak at 4h), this does not result in sufficient 
induction of A20, which may suggest another mechanism for repressing 
A20 induction. However, as we had only very few CF PNECs in our 
subgroups, we were only able to describe our observations here. Further 
investigations are needed to be able to apply statistical analyses to the 
p38 expression levels in CF PNECs. 
In summary, our data suggest that in CF airway epithelial cells NF-
κB together with other pro-inflammatory pathways such as MAPK-p38 
are responsible for the sustained high levels of pro-inflammatory 
cytokine release when stimulated with LPS. A20 inducing compounds 
such as GA3 have been shown to have anti-inflammatory effects through 
reducing NF-κB activation [41] but in CF PNECs the otherwise anti-
inflammatory A20 induction by GA3 might be modified or overwritten 
by pre-existing p38 levels, resulting in a pro-inflammatory effect of 
GA3, but the underlying mechanisms still need further investigation. 
More so, the cause for the basal and LPS stimulated lack of A20 in 
CF airway epithelial cells is still unknown. Recent data suggest that 
factors regulating A20 translation may also play a role in disease or cell 
specific A20 levels [51]. However, our data suggest a possible role for 
personalised anti-p38 treatment as identified high p38 expressing CF 
patients may benefit from therapeutics targeting p38 as described by 
Raia et al. [48].
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